- Home
- RIGL vs NGS Comparison
RIGL vs NGS Comparison
Compare RIGL & NGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | NGS |
|---|---|---|
| Founded | 1996 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oilfield Services/Equipment |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.7M | 475.1M |
| IPO Year | 2000 | 2006 |
Fundamental Metrics
Financial Performance| Metric | RIGL | NGS |
|---|---|---|
| Price | $29.20 | $42.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $45.67 | $40.67 |
| AVG Volume (30 Days) | ★ 386.9K | 83.0K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 1.08% |
| EPS Growth | ★ 1867.68 | 14.60 |
| EPS | 0.44 | ★ 0.53 |
| Revenue | ★ $294,282,000.00 | $172,315,000.00 |
| Revenue This Year | N/A | $15.05 |
| Revenue Next Year | $12.75 | $9.52 |
| P/E Ratio | ★ $66.97 | $79.53 |
| Revenue Growth | ★ 64.15 | 9.94 |
| 52 Week Low | $18.14 | $22.72 |
| 52 Week High | $52.24 | $44.12 |
Technical Indicators
Market Signals| Indicator | RIGL | NGS |
|---|---|---|
| Relative Strength Index (RSI) | 49.56 | 59.50 |
| Support Level | $28.08 | $32.52 |
| Resistance Level | $32.17 | N/A |
| Average True Range (ATR) | 1.99 | 1.54 |
| MACD | 0.05 | 0.07 |
| Stochastic Oscillator | 48.15 | 70.61 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About NGS Natural Gas Services Group Inc.
Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.